Sanofi reaps first fruit of Abl­ynx buy­out with a Eu­ro­pean OK for its lead rare dis­ease drug

Just weeks af­ter clos­ing its $4.8 bil­lion ac­qui­si­tion of Abl­ynx, Sanofi has bagged a Eu­ro­pean ap­proval for its lead drug, capla­cizum­ab, which treats an ul­tra-rare blood clot­ting dis­ease.

The OK — based on a pair of Phase II and Phase III stud­ies — marks the first reg­u­la­to­ry val­i­da­tion for Abl­ynx’s plat­form tech for small “nanobod­ies” that are a sliv­er of the size of reg­u­lar an­ti­bod­ies.

Capla­cizum­ab treats ac­quired throm­bot­ic throm­bo­cy­topenic pur­pu­ra (aTTP), a dis­or­der char­ac­ter­ized by blood clots in small blood ves­sels that trig­gers low platelet counts. Re­searchers found that the drug sig­nif­i­cant­ly re­duced the time it took for the platelet counts to re­turn to nor­mal and low­ered the the per­cent­age of pa­tients who died or saw the dis­ease re­cur.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.